READ
J Clin Microbiol. 2011 June; 49(6): 2151–2153.
doi: 10.1128/JCM.00256-11
PMCID: PMC3122746
Sarah P. Hammond,1,3,4,* Ralf Bialek,5 Danny A. Milner,2,4 Eva M. Petschnigg,1,† Lindsey R. Baden,1,3,4 and
INTRODUCTION
The reported incidence of mucormycosis (previously referred to as
zygomycosis) (6) has been increasing in the last 2 decades,
particularly among immunocompromised patients (3, 11, 12). In a recent study of invasive fungal disease
in hematopoietic stem cell transplant (HSCT) recipients, mucormycosis was the
third most common infection, after candidiasis and aspergillosis (8).
Despite its increasing frequency, mucormycosis remains difficult to
diagnose. Radiographically and clinically, mucormycosis is often
indistinguishable from other common invasive mold infections, such as
aspergillosis. Histopathology is the “gold standard” for diagnosis. However,
histopathologic identification of Mucorales in tissue specimens requires
significant pathological expertise and does not allow species identification.
Organisms in tissue specimens with histopathologically identified mucormycosis
often fail to grow in fungal cultures. In a review of 929 cases of mucormycosis
reported between 1940 and 2003, only 50% were culture positive (11).
The inability to confirm histopathologically diagnosed mucormycosis and
determine the species has important treatment implications. In comparison to Aspergillus
species, which are
typically susceptible to voriconazole, amphotericin B, and echinocandins,
Mucorales are usually susceptible only to amphotericin B and less frequently to
posaconazole (1). Furthermore, there is significant variability
in susceptibility by genus; in a study of 217 clinical isolates of Mucorales,
100% ofLichtheimia spp. (syn. Absidia pro parte), Rhizomucor spp., and Rhizopus spp. were susceptible to amphotericin B, while
only 63% of Cunninghamella sp. isolates were susceptible (1). Thus, novel techniques to confirm the
diagnosis of mucormycosis in tissue and identify the infecting species are
needed.
Detection of fungal DNA in tissue samples by PCR is a novel
non-culture-based method that may allow improved diagnosis of mucormycosis (2, 4, 7, 9, 10). In particular, PCR with sequencing of the 18S
ribosomal DNA of Mucorales in order to diagnose mucormycosis and identify the
infecting species in paraffin-embedded tissue samples in clinical cases of
invasive fungal infection has been described (2, 9, 10). We assessed the performance of Mucorales 18S
ribosomal DNA PCR and sequencing in a retrospective cohort of patients treated
for hematological malignancies with histopathologically proven mucormycosis.
(This work was presented in abstract form at the 50th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 12 September
2010, abstr. M-414.)
MATERIALS AND METHODS
Patients and
definitions.
All adult patients with hematologic malignancy and HSCT recipients at
Brigham and Women's Hospital/Dana-Farber Cancer Institute (BWH/DFCI) who
developed proven mucormycosis between 1 January 2001 and 31 December 2009 were
identified. Computerized medical records were reviewed for underlying
hematologic diagnosis, stem cell transplant status, microbiologic results,
pathological results (from tissue aspirates, biopsy specimens, or autopsy
specimens), and radiographic results. This study was approved by the Partners
Healthcare Human Research Committee.
The routine clinical approach to patients with suspected invasive mold
infection in whom serum fungal antigens (galactomannan beginning in 2003 and 1→3-β-d-glucan beginning in 2004) do not suggest a diagnosis at BWH/DFCI includes
surgical biopsy or computed tomography-guided collection of a fine-needle
aspirate of the affected area. Proven mucormycosis was defined by use of the
European Organization for Research and Treatment of Cancer/Mycosis Study Group
criteria on the basis of pathological assessment of tissue samples at the time
that the sample was collected (5). Mucormycosis was considered disseminated if
there was radiographic evidence of infection in two or more noncontiguous
sites.
Histopathology.
Histopathologic analysis of biopsy specimens and cytopathologic analysis of
fine-needle aspirate specimens were performed on formalin-fixed
paraffin-embedded samples by an anatomic pathologist at the time that the
tissue specimen was obtained. All tissue samples were fixed in 10%
neutral-buffered formalin and processed per routine protocols to paraffin
blocks. The cohort included all cases in which this initial pathological
assessment suggested mucormycosis. All available samples were reviewed a second
time by an infectious disease pathologist (D.A.M.) at the time that the study
was completed for confirmation. The histological sections examined by the
infectious disease pathologist were the same sections analyzed at initial
diagnosis by the primary pathologist. The primary pathologists and the expert
infectious disease pathologist were blinded to PCR results.
Fungal culture.
Routine fungal cultures were performed on all biopsy, aspirate, and autopsy
specimens. In cases where tissue culture yielded growth of a fungus, isolated
pathogens were identified by standard phenotypic methods. Confirmatory species
identification of most isolates was performed using phenotypic methods at a
national reference laboratory (Fungus Testing Laboratory, University of Texas
Health Science Center at San Antonio, San Antonio, TX).
Molecular methods.
DNA extraction and seminested PCR targeting the 18S ribosomal DNA of
Mucorales, the mitochondrial DNA of Aspergillus species, and the human beta-globulin gene
(extraction control) were performed on formalin-fixed paraffin-embedded tissue
specimens (including biopsy specimens and cell blocks from fine-needle
aspirates) as previously described (2, 9). The primers are located within the V4 and V5
variable regions of the 18S ribosomal DNA. The outer primers ZM1 (5′-ATT ACC
ATG AGC AAA TCA GA-3′) and ZM2 (5′-TCC GTC AAT TCC TTT AAG TTT C-3′) are
complementary to nucleotide positions 711 to 730 and 1117 to 1096 (Rhizopus arrhizus, GenBank accession number AF113440), respectively. Products of the seminested
reaction using primers ZM1 and ZM3 (5′-CAA TCC AAG AAT TTC ACC TCT AG-3′) are
175 to 177 bp long and demonstrate enough variability to reliably identify
genera but not enough to distinguish species unequivocally.
All PCR testing was performed retrospectively at the time that the study
was completed. Tissue sections used for DNA extraction and PCR amplification
were cut from the existing tissue block at the time that the study was
initiated in 2010 (months to years after original collection) using a fresh
sterile blade and sterile tubes for collection and transport to the molecular
lab. For each tissue specimen, at least two extractions and PCRs were performed
on each of the two 5-micrometer tissue slices. In cases where multiple tissue
specimens were available from the same diagnostic procedure, up to four
separate samples per case were assayed. Mucorales andAspergillus PCR products were sequenced as previously
described (2). Investigators who performed the PCR assays
and sequencing were blinded to clinical information and tissue culture results.
Analysis.
Concordance of pathological, microbiologic, and Mucorales PCR sequencing
results were assessed to determine the order and genus in cases where cultures
grew a mold of the order Mucorales. In cases where cultures did not grow, the
ability of PCR to identify the infecting mold to the genus level was assessed.
The performance characteristics of Mucorales PCR and culture were compared by
McNemar's test. Statistical analysis was performed using SAS (version 9.2)
software (SAS Institute Incorporated, Cary, NC).
RESULTS
During the study period, proven mucormycosis was diagnosed in 29 patients
on the basis of initial pathological review at the time of the clinical
illness. The cohort included 14 patients with hematologic malignancy and 15
HSCT recipients. Diagnosis was made by tissue biopsy in 21 patients,
fine-needle tissue aspiration in 3 patients, and autopsy in 5 patients. There
were 12 episodes of disseminated infection and 17 episodes of localized
infection, including 9 sino-orbital infections, 6 pulmonary infections, and 2
cutaneous infections.
Fungal tissue cultures grew Mucorales in 13 of 29 cases, including Rhizopus spp. (n = 5), Mucor spp. (n = 3), Cunninghamella spp. (n = 2), Rhizomucor spp. (n = 2), andLichtheimia spp. (n = 1). One tissue sample from a patient with sino-orbital infection grew
both Mucor
circinelloides and Curvularia
clavata.
Among the 13 cases where both cultures grew Mucorales and initial review of
tissue pathology was consistent with mucormycosis, 12 specimens were available
when the study was performed for PCR assays and expert pathological review (Fig. 1). Ten of 12 were
Mucorales PCR positive, and sequencing results for 9 of these were concordant
with culture results to the genus level. All 12 samples were Aspergillus PCR negative, and all 12 appeared to have
infections consistent with mucormycosis on expert pathological review. One case
was PCR positive for mucormycosis, but the sequencing result, Rhizomucor spp., was discordant at the genus level with the
culture result,Mucor spp. The cultured
fungus in this case was identified locally, but the isolated species was not
sent to the reference laboratory for confirmation. Two of 12 cases in which
cultures grew Mucorales were PCR negative, including 1 case that was also human
beta-globulin PCR (control) negative.
Results of Mucorales and Aspergillus PCR and expert pathological review. path,
pathological; AspPCR,Aspergillus PCR; *, one tissue
sample each from the culture-positive and culture-negative groups was not
available for pathological review and PCR at ...
Among the 16 cases where mucormycosis was diagnosed on the basis of initial
review of tissue histopathology alone, 15 paraffin-embedded specimens were
available at the time that the study was performed for PCR with sequencing and
expert pathological review (Fig. 1). Twelve of 15
samples were Mucorales PCR positive, and the findings of expert pathological
review were consistent with mucormycosis in 10 of these 12 samples. Sequencing
identified the following Mucorales: Rhizopus spp. (n = 4),Cunninghamella spp. (n = 4), Rhizomucor spp. (n = 3), and Lichtheimia spp. (n = 1).
Three of 15 culture-negative cases were Mucorales PCR negative. Two of
these three were Aspergillus PCR negative; expert pathological review of these two cases suggested
mucormycosis in one case, and the infection could not be identified further
than an invasive mold infection in the other. The third culture-negative
Mucorales PCR-negative case was Aspergillus PCR positive, with Aspergillus flavus identified by sequencing. Blinded expert pathological review of this case
also suggested invasive aspergillosis.
Among the five cases in which Mucorales PCR did not amplify, one sample
each was from 2001, 2004, and 2005 and two samples were from 2009; thus, there
was no relationship between the age of the sample and Mucorales PCR negativity.
Overall, Mucorales PCR was positive in 22 of 27 tissue specimens that were
assessed. In comparison to tissue culture, Mucorales PCR was significantly more
likely to confirm mucormycosis in pathologically defined cases (P = 0.008).
DISCUSSION
These data demonstrate that Mucorales PCR of formalin-fixed
paraffin-embedded tissue can be a useful tool for confirmation of pathological
diagnosis of mucormycosis. Among 27 tissue specimens with initial histologic
evidence of mucormycosis, Mucorales PCR was positive in 22 specimens.
Furthermore, we found a high rate of concordance among 12 specimens in which
tissue culture grew Mucorales: PCR confirmed mucormycosis in 10 (83%), and the
sequencing result was concordant with the culture result at the genus level in
9 specimens. Comparison of Mucorales PCR results to those of microbiologic
culture strongly suggests the accuracy of this technique and allowed
identification of the infecting mold in 12 culture-negative cases in this
cohort. The present study confirms and extends findings from previous studies
which assessed the performance of this technique in a limited number of cases
of solely histopathologically identified mucormycosis (2, 9) and in culture-proven cases with
non-formalin-fixed specimens (9, 10). Our data demonstrate that Mucorales PCR with
sequencing offers a reliable way to confirm tissue diagnosis of mucormycosis
and to identify the infecting species, thereby allowing targeted antifungal
therapy.
Mucorales PCR was negative in 5 tissue specimens with initial
histopathologic evidence of mucormycosis. These negative samples included one
tissue specimen that was repeatedly Aspergillus PCR positive and that appeared to a blinded
expert pathologist to have an infection consistent with invasive aspergillosis,
suggesting that the initial pathological diagnosis of mucormycosis made at the
time of infection may have been incorrect. Another negative specimen was both Aspergillus PCR negative and human beta-globulin (control)
PCR negative, suggesting that the DNA in the specimen was destroyed in the
process of fixation, sample storage, or DNA extraction. The remaining three
Mucorales PCR-negative specimens were control PCR positive and Aspergillus PCR negative. On expert pathological review, the
findings for one of these specimens, in which there was limited tissue, was not
characteristic for mucormycosis or aspergillosis. These negative Mucorales PCR
results may be due to technical factors, such as a limited amount of fungal DNA
in small tissue specimens or degradation of fungal DNA, particularly in the
older specimens in this retrospective study. In addition, the negative
Mucorales PCR result in the case where the infection was not characteristic for
mucormycosis or aspergillosis on expert pathological review suggests possible
infection due to a less common other mold (e.g., Fusarium spp.).
In summary, Mucorales PCR of formalin-fixed paraffin-embedded tissue
samples with sequencing had a high rate of concordance with tissue culture to
the genus level and allowed diagnostic confirmation and species identification
in 12 of 15 cases of mucormycosis diagnosed solely on the basis of histopathology.
This is a useful tool that can improve tissue diagnosis of mucormycosis and
characterization of culture-negative invasive mold infection, thus facilitating
targeted antifungal therapy.
ACKNOWLEDGMENTS
We declare no competing financial interests.
We acknowledge the excellent technical assistance of Veronika Lucht and
Maria Hinz.
FOOTNOTES
Published ahead of print on 20 April 2011.
REFERENCES
1. Almyroudis N. G., Sutton D. A., Fothergill
A. W., Rinaldi M. G., Kusne S. 2007. In vitro susceptibilities of 217
clinical isolates of zygomycetes to conventional and new antifungal
agents. Antimicrob. Agents Chemother. 51:2587–2590. [PMC free article][PubMed]
2. Bialek R., et al. 2005. PCR based
identification and discrimination of agents of mucormycosis and aspergillosis
in paraffin wax embedded tissue. J. Clin. Pathol.58:1180–1184. [PMC free article] [PubMed]
3. Bitar D., et al. 2009. Increasing
incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg. Infect.
Dis. 15:1395–1401. [PMC free article] [PubMed]
4. Dannaoui E., et al. 2010. Molecular detection and identification of
zygomycetes species from paraffin-embedded tissues in a murine model of
disseminated zygomycosis: a collaborative European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group
(EFISG) evaluation. J. Clin. Microbiol. 48:2043–2046. [PMC free article] [PubMed]
5. De Pauw B., et al. 2008. Revised
definitions of invasive fungal disease from the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis.46:1813–1821. [PMC free article] [PubMed]
6. Hibbett D. S., et al. 2007. A
higher-level phylogenetic classification of the Fungi.Mycol.
Res. 111:509–547. [PubMed]
7. Kasai M., et al. 2008. Detection of a
molecular biomarker for zygomycetes by quantitative PCR assays of plasma,
bronchoalveolar lavage, and lung tissue in a rabbit model of experimental
pulmonary zygomycosis. J. Clin. Microbiol. 46:3690–3702.[PMC free article] [PubMed]
8. Kontoyiannis D. P., et al. 2010. Prospective surveillance for invasive fungal
infections in hematopoietic stem cell transplant recipients, 2001-2006:
overview of the Transplant-Associated Infection Surveillance Network (TRANSNET)
Database. Clin. Infect. Dis. 50:1091–1100. [PubMed]
9. Rickerts V., et al. 2006. Diagnosis
of invasive aspergillosis and mucormycosis in immunocompromised patients by
seminested PCR assay of tissue samples. Eur. J. Clin. Microbiol. Infect.
Dis. 25:8–13. [PubMed]
10. Rickerts V., et al. 2007. Comparison
of histopathological analysis, culture, and polymerase chain reaction assays to
detect invasive mold infections from biopsy specimens. Clin. Infect.
Dis. 44:1078–1083. [PubMed]
11. Roden M. M., et al.
2005. Epidemiology and outcome of zygomycosis: a review of 929 reported
cases. Clin. Infect. Dis. 41:634–653. [PubMed]
12. Saegeman V., et al. 2010. Increasing
incidence of mucormycosis in university hospital, Belgium. Emerg. Infect.
Dis. 16:1456–1458. [PMC free article] [PubMed]
Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)